Drug Trial Radar · NCT06344091
A Study of Bupivacaine Liposome Injection in Local Analgesia of Pediatric Patients
Last checked: Nov 20, 2026Latest source record: Sep 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
232
Planned (sponsor's estimate)
Start
May 21, 2024
Primary completion
May 2027
Study completion May 2027
Sponsor
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 3, 2024
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 6 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is being conducted to evaluate the safety and efficacy of bupivacaine liposome injection for local infiltration analgesia in pediatric orthopedic surgery in the real world.
Conditions
- Local Analgesia Via Infiltration
Interventions
Bupivacaine Liposome InjectionDrug
Bupivacaine Liposome Injection 4 mg/kg (up to a maximum of 266 mg)
Primary outcomes
What the sponsor says the trial is designed to measure.
- The incidence of Treatment Emergent Adverse events (TEAE) in the cardiac and nervous systemTime frame: 0 minute to 14 days after administration
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Guangzhou Women and Children's Medical Center
Guangzhou, Guangdong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.